Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Dosintervallstudie av ORKA-001 hos patienter med måttlig till svår plackpsoriasis (EVERLAST-B)

3 november 2026 uppdaterad av: Oruka Therapeutics, Inc.

En multicenter, randomiserad, dubbelblind, placebokontrollerad, dosintervallbestämmande studie av ORKA-001 hos deltagare med måttlig till svår plackpsoriasis

This is a multicenter, randomized, double-blinded, placebo-controlled, dose-range finding study to evaluate the efficacy and safety of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis.

Studieöversikt

Status

Aktiv, inte rekryterande

Betingelser

Detaljerad beskrivning

This is a multicenter, randomized, double-blinded, placebo-controlled, dose ranging study designed to identify the optimal induction dosing regimen of ORKA-001 in approximately 160 adult participants with moderate-to-severe plaque psoriasis.

The study will evaluate the efficacy and safety of 3 induction dosing regimens of ORKA-001 compared to placebo and will include 3 maintenance regimens.

The study will consist of 4 periods:

  • Screening Period of up to 6 weeks
  • Induction Period of up to 28 weeks (Day 1 [Baseline] to Week 28)
  • Maintenance Period of up to approximately 72 weeks (Week 28 to Week 100)
  • Post-treatment Follow-up Period: Participants will have the option to enter the open-label extension (OLE) study. Participants who opt out of the OLE study and/or withdraw from the study must be followed for 48 weeks after the End of Treatment (EOT)/Early Termination (ET) visit.

Studietyp

Interventionell

Inskrivning (Beräknad)

160

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

    • Arizona
      • Phoenix, Arizona, Förenta staterna, 85032
        • Oruka Therapeutics Investigative Site
    • Arkansas
      • North Little Rock, Arkansas, Förenta staterna, 72117
        • Oruka Therapeutics Investigative Site
    • California
      • Los Angeles, California, Förenta staterna, 90045
        • Oruka Therapeutics Investigative Site
      • Los Angeles, California, Förenta staterna, 90024
        • Oruka Therapeutics Investigative Site
      • San Diego, California, Förenta staterna, 92123
        • Oruka Therapeutics Investigative Site
    • Florida
      • Miami, Florida, Förenta staterna, 33126
        • Oruka Therapeutics Investigative Site
    • Illinois
      • Rolling Meadows, Illinois, Förenta staterna, 60008
        • Oruka Therapeutics Investigative Site
    • Indiana
      • Plainfield, Indiana, Förenta staterna, 46168
        • Oruka Therapeutics Investigative Site
    • Maryland
      • Rockville, Maryland, Förenta staterna, 20850
        • Oruka Therapeutics Investigative Site
    • New York
      • Kew Gardens, New York, Förenta staterna, 11415
        • Oruka Therapeutics Investigative Site
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27516
        • Oruka Therapeutics Investigative Site
    • Ohio
      • Cleveland, Ohio, Förenta staterna, 44106
        • Oruka Therapeutics Investigative Site
      • Mason, Ohio, Förenta staterna, 45040
        • Oruka Therapeutics Investigative Site
    • Oregon
      • Portland, Oregon, Förenta staterna, 97201
        • Oruka Therapeutics Investigative Site
      • Portland, Oregon, Förenta staterna, 97210
        • Oruka Therapeutics Investigative Site
    • Pennsylvania
      • Philadelphia, Pennsylvania, Förenta staterna, 19104
        • Oruka Therapeutics Investigative Site
    • Texas
      • Frisco, Texas, Förenta staterna, 75033
        • Oruka Therapeutics Investigative Site
      • Houston, Texas, Förenta staterna, 77004
        • Oruka Therapeutics Investigative Site
      • Webster, Texas, Förenta staterna, 77598
        • Oruka Therapeutics Investigative Site
    • Virginia
      • Norfolk, Virginia, Förenta staterna, 23502
        • Oruka Therapeutics Investigative Site
    • British Columbia
      • Surrey, British Columbia, Kanada, V3R 6A7
        • Oruka Therapeutics Investigative Site
      • Surrey, British Columbia, Kanada, V3V 0C6
        • Oruka Therapeutics Investigative Site
    • New Brunswick
      • Fredericton, New Brunswick, Kanada, E3B 1G9
        • Oruka Therapeutics Investigative Site
    • Ontario
      • Ajax, Ontario, Kanada, L1S 7K8
        • Oruka Therapeutics Investigative Site
      • Markham, Ontario, Kanada, L3P 1X3
        • Oruka Therapeutics Investigative Site
      • Peterborough, Ontario, Kanada, K9J 5K2
        • Oruka Therapeutics Investigative Site
    • Quebec
      • Montreal, Quebec, Kanada, HZX 2V1
        • Oruka Therapeutics Investigative Site
      • Québec, Quebec, Kanada, G1V 4X7
        • Oruka Therapeutics Investigative Site
    • Barcelona
      • Badalona, Barcelona, Spanien, 08916
        • Oruka Therapeutics Investigative Site
      • Barcelona, Barcelona, Spanien, 08041
        • Oruka Therapeutics Investigative Site
    • Madrid
      • Madrid, Madrid, Spanien, 28002
        • Oruka Therapeutics Investigative Site
      • Madrid, Madrid, Spanien, 28046
        • Oruka Therapeutics Investigative Site
    • Baden-Wuerrtemberg
      • Heidelberg, Baden-Wuerrtemberg, Tyskland, 69120
        • Oruka Therapeutics Investigative Site
    • Hesse
      • Frankfurt am Main, Hesse, Tyskland, 60590
        • Oruka Therapeutics Investigative Site
    • Lower Saxony
      • Bad Bentheim, Lower Saxony, Tyskland, 48455
        • Oruka Therapeutics Investigative Site
    • Schleswig-Holstein
      • Kiel, Schleswig-Holstein, Tyskland, 24105
        • Oruka Therapeutics Investigative Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år och äldre (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Inclusion Criteria:

  1. Participants ≥ 18 years of age

  2. Have a diagnosis of plaque psoriasis for > 6 months

  3. Have moderate-to-severe chronic plaque psoriasis defined as:

    1. BSA ≥ 10%, and
    2. PASI ≥ 12, and
    3. IGA score of ≥ 3 on a 5-point scale
  4. Candidate for systemic therapy or phototherapy

  5. Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  1. Nonplaque forms of psoriasis (including guttate, erythrodermic, or pustular) or drug-induced psoriasis
  2. Significant history or clinical manifestation of any metabolic, other dermatological, hepatic, renal, hematologic, pulmonary, cardiovascular, gastrointestinal, neurologic, respiratory, endocrine, or psychiatric disorder, or any infectious disease
  3. History of malignancy, except for non-melanoma skin cancer or cancer curatively treated ≥ 5 years, without evidence of recurrence
  4. A known hypersensitivity to any components of the ORKA-001 drug product
  5. Women who are breastfeeding or plan to breastfeed during the study

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Dubbel

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: (Induction Period - Arm 1) ORKA-001

Participants will receive 37.5 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Experimentell: (Induction Period - Arm 2) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Experimentell: (Induction Period - Arm 3) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Induction regimen.

ORKA-001 administered by subcutaneous (SC) injection

Placebo-jämförare: (Induction Period - Arm 4) Placebo

Participants will receive Placebo per protocol Induction regimen.

Placebo administered by subcutaneous (SC) injection

Experimentell: (Maintenance Period - Arm 1) ORKA-001

Participants will receive 300 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Experimentell: (Maintenance Period - Arm 2) ORKA-001

Participants will receive 600 mg ORKA-001 per protocol Maintenance regimen, based on protocol defined response.

ORKA-001 administered by subcutaneous (SC) injection

Placebo-jämförare: (Maintenance Period - Arm 3) Placebo

Participants will receive Placebo per protocol Maintenance regimen, based on protocol defined response.

Placebo administered by subcutaneous (SC) injection

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Participants Achieving 100% Reduction in PASI Score at Week 16
Tidsram: Week 16

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Proportion of Participants Who Achieve an IGA = 0 (Clear) at Week 16
Tidsram: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Achieving 90% Reduction in PASI Score at Week 16
Tidsram: Week 16

Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 16
Proportion of Participants Who Achieve an IGA = 0 (Clear) or 1 (Almost Clear) at Week 16
Tidsram: Week 16

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 16
Proportion of Participants Maintaining 100% Reduction in PASI Score at Week 100
Tidsram: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) at Week 100
Tidsram: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 90% Reduction in PASI Score at Week 100
Tidsram: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Proportion of Participants Maintaining an IGA = 0 (Clear) or 1 (Almost Clear) at Week 100
Tidsram: Week 100

The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4).

Week 100
Proportion of Participants Maintaining 75% Reduction in PASI Score at Week 100
Tidsram: Week 100

The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease).

Week 100
Incidence of Treatment-emergent Adverse Events (TEAEs) and TEAEs of Special Interest (TEAESIs)
Tidsram: Day 1 through Week 100

Incidence of treatment adverse events, treatment adverse events of special interest, and clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms

Day 1 through Week 100

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

3 december 2025

Primärt slutförande (Faktisk)

21 oktober 2026

Avslutad studie (Beräknad)

1 december 2028

Studieregistreringsdatum

Först inskickad

16 december 2025

Först inskickad som uppfyllde QC-kriterierna

16 december 2025

Första postat (Faktisk)

18 december 2025

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 november 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 november 2026

Senast verifierad

1 oktober 2026

Mer information

Termer relaterade till denna studie

Andra studie-ID-nummer

  • ORKA-001-114

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera